NorthRock Partners LLC Sells 1,533 Shares of Boston Scientific Corporation $BSX

NorthRock Partners LLC reduced its position in Boston Scientific Corporation (NYSE:BSX) by 9.3% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 14,947 shares of the medical equipment provider’s stock after selling 1,533 shares during the period. NorthRock Partners LLC’s holdings in Boston Scientific were worth $1,605,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in BSX. Vanguard Group Inc. grew its holdings in Boston Scientific by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock valued at $13,577,311,000 after buying an additional 1,697,945 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Boston Scientific by 18.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock valued at $1,070,387,000 after buying an additional 1,664,108 shares in the last quarter. Swedbank AB grew its holdings in Boston Scientific by 114.5% during the 2nd quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider’s stock valued at $302,816,000 after buying an additional 1,505,019 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Boston Scientific by 10.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock valued at $1,426,779,000 after buying an additional 1,383,524 shares in the last quarter. Finally, Ninety One UK Ltd grew its holdings in Boston Scientific by 33.5% during the 2nd quarter. Ninety One UK Ltd now owns 5,146,218 shares of the medical equipment provider’s stock valued at $552,755,000 after buying an additional 1,290,414 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Down 0.5%

Shares of BSX opened at $94.92 on Tuesday. The firm has a market cap of $140.64 billion, a P/E ratio of 56.50, a P/E/G ratio of 2.30 and a beta of 0.61. The stock has a 50 day simple moving average of $101.75 and a two-hundred day simple moving average of $101.84. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the prior year, the firm earned $0.62 earnings per share. Boston Scientific’s revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

BSX has been the topic of several research analyst reports. Canaccord Genuity Group upped their price objective on shares of Boston Scientific from $131.00 to $132.00 and gave the stock a “buy” rating in a research report on Wednesday, October 1st. Jefferies Financial Group restated a “hold” rating on shares of Boston Scientific in a research report on Monday, July 21st. Barclays upped their price objective on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. Erste Group Bank cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Finally, UBS Group upped their price objective on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday, July 24th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $120.71.

Insider Buying and Selling

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares in the company, valued at $17,561,336.74. This represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. This represents a 42.32% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 174,214 shares of company stock worth $17,972,457. Company insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.